Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744612 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT02744612 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 39 participants.
The verdict
NCT02744612, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as brentuximab vedotin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.
Interventions
- DRUG Brentuximab Vedotin
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-06-20 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744612
The ClinicalTrials.gov registry entry for NCT02744612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brentuximab Vedotin is the first listed.
NCT02744612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744612 about?
NCT02744612 is a clinical study titled "Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Imm...
What is the current status of trial NCT02744612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2016-06-20. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT02744612?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02744612?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.